Decreased TESK1-mediated cofilin 1 phosphorylation in the jejunum of IBS-D patients may explain increased female predisposition to epithelial dysfunction by Rodiño-Janeiro, Bruno K. et al.
1SCIENTIFIC RepoRts |  (2018) 8:2255  | DOI:10.1038/s41598-018-20540-9
www.nature.com/scientificreports
Decreased TESK1-mediated cofilin 
1 phosphorylation in the jejunum 
of IBS-D patients may explain 
increased female predisposition to 
epithelial dysfunction
Bruno K. Rodiño-Janeiro  1, Cristina Martínez1, Marina Fortea2, Beatriz Lobo1, Marc Pigrau1, 
Adoración Nieto1, Ana María González-Castro2, Eloísa Salvo-Romero1,2, Danila Guagnozzi2, 
Cristina Pardo-Camacho2, Cristina Iribarren2, Fernando Azpiroz  1,3, Carmen Alonso-Cotoner1,3, 
Javier Santos1,3 & Maria Vicario2,3
Disturbed intestinal epithelial barrier and mucosal micro-inflammation characterize irritable bowel 
syndrome (IBS). Despite intensive research demonstrating ovarian hormones modulation of IBS 
severity, there is still limited knowledge on the mechanisms underlying female predominance in this 
disorder. Our aim was to identify molecular pathways involved in epithelial barrier dysfunction and 
female predominance in diarrhea-predominant IBS (IBS-D) patients. Total RNA and protein were 
obtained from jejunal mucosal biopsies from healthy controls and IBS-D patients meeting the Rome 
III criteria. IBS severity was recorded based on validated questionnaires. Gene and protein expression 
profiles were obtained and data integrated to explore biological and molecular functions. Results 
were validated by western blot. Tight junction signaling, mitochondrial dysfunction, regulation 
of actin-based motility by Rho, and cytoskeleton signaling were differentially expressed in IBS-
D. Decreased TESK1-dependent cofilin 1 phosphorylation (pCFL1) was confirmed in IBS-D, which 
negatively correlated with bowel movements only in female participants. In conclusion, deregulation of 
cytoskeleton dynamics through TESK1/CFL1 pathway underlies epithelial intestinal dysfunction in the 
small bowel mucosa of IBS-D, particularly in female patients. Further understanding of the mechanisms 
involving sex-mediated regulation of mucosal epithelial integrity may have significant preventive, 
diagnostic, and therapeutic implications for IBS.
In recent years, the conventional view of irritable bowel syndrome (IBS) as a non-organic disorder has been chal-
lenged by several reports showing the presence of neuronal damage, altered neuroplasticity, microbial dysbiosis 
and barrier dysfunction along with alterations in the expression and localization of intestinal epithelial tight 
junction (TJ) proteins1. Additionally, a low-grade infiltration of mast cells, lymphocytes and plasma cells and 
immune activation has been identified in the lamina propria of both large and small bowel mucosa, particularly 
in diarrhea-predominant IBS patients (IBS-D)2–4. Although, the true origin of the intestinal micro-inflammation 
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and immune activation observed in IBS patients is still unknown, a potential pathophysiological link to these 
findings could be the alteration of the epithelial barrier function, that would lead to disturbed mucosal homeo-
stasis1,5–7. In this line, we and others have recently shown altered expression, phosphorylation and localization of 
core TJ proteins, increased intercellular space and cytoskeleton condensation in jejunal and colonic epithelium 
of IBS8. These abnormalities may be partly mediated by mast cells through the activation of protease activated 
receptor 2 (PAR2), which can regulate epithelial barrier function, myosin light chain (MLC) phosphorylation 
and the expression of cytoskeleton proteins9. PAR2 is activated by serine proteases-mediated cleavage, and these, 
including tryptase and trypsin, have been shown to be enhanced in the jejunal fluid, feces and supernatants from 
colonic biopsies of IBS-D10. Moreover, PAR2 epithelial basolateral pools can regulate the actin depolymerization 
through cofilin 1 (CFL1) by beta-arrestin11. CFL1 has a leading role in actin depolymerization on the barbed 
end12 and can modulate epithelial permeability by TJ regulation11,13,14 and epithelial cell interactions with extra-
cellular matrix15, events that could be related to cytoskeleton deregulation as observed in the jejunum of IBS-D6,7. 
Notably, phosphorylation of CFL1 by specific kinases LIMK and TESK116,17 inactivates actin depolymerization 
which, in turn, is regulated by Rho GTPases and integrin/vinculin signaling, respectively18.
High throughput molecular techniques, such as microarray profiling and RNAseq, followed by accurate analy-
sis of the associated biological pathways have provided new insights on the molecular mechanisms involved in the 
pathophysiology of IBS6,19–23. Proteomic tools and related strategies have been recently applied to profile protein 
expression in urine samples from IBS patients24 and in the colonic mucosa and the neuromuscular layer from rat 
models mimicking IBS clinical manifestations25,26. However, a comprehensive proteomic profiling in intestinal 
tissue from IBS patients has not been performed so far.
Our hypothesis was that alterations in molecular pathways modulating epithelial barrier dysfunction deter-
mine the female predominance observed in IBS-D patients. To test our hypothesis, we have applied an integra-
tive multi-omics approach combining data from transcriptomic and proteomic profiling analysis in the jejunal 
mucosa of IBS-D patients vs. healthy controls further subdividing groups by sex.
Results
The jejunal mucosa of IBS-D shows a distinctive proteomic profile. Sixteen healthy controls and 15 
IBS-D patients were included in the study (Table 1). Proteomic profiling was performed first in a subset of subjects 
comprising 4 healthy controls and 4 IBS-D. Analysis of data revealed approximately 1,200 protein spots. By select-
ing abundance ratio of 1.3-fold as the threshold for the study, 139 spots were differentially produced between the 
two groups studied (P < 0.05). A search for protein identification was performed by introducing the obtained 
sequences from 139 spots in public databases, from which 64 proteins were identified (Fig. 1; Supplementary 
Table 2). IPA analysis revealed key pathways for intestinal homeostasis as playing an important role in IBS-D. 
Lipopolysaccharide (LPS)/interleukin 1 (IL1)-mediated alterations of nuclear retinoid x receptor (RXR) recep-
tors, mitochondrial dysfunction and regulation of actin-based motility by Rho, appeared as the most significant 
pathways related to IBS-D proteomic profile (Table 2). Other significant pathways were also found to be related 
with alterations in actin-cytoskeleton function as clathrin-mediated endocytosis signaling, actin cytoskeleton sig-
naling, caveolar-mediated endocytosis signaling and integrin signaling. In addition, the most significant protein 
network identified showed CFL1 as playing a key role by interacting with other proteins involved in the regulation 
of the actin cytoskeleton (Fig. 2A). As shown in Fig. 2B, CFL1 is tightly regulated by kinases and phosphatases 
activity. When CFL1 is phosphorylated in the serine 3 residue by TESK1 or LIMK, CFL1 is inactivated and, 
generally, translocated to the cell nucleus. As mentioned before, the activity of these kinases can be regulated by 
RhoGTPases (regulation of LIMK) or by integrin signaling through vinculin (VCL) (regulation of TESK1).
Integrated protein/gene expression analysis reveals convergence of canonical pathways, bio-
logical functions and disease mechanisms in the jejunal mucosa of IBS-D. In a previous work, 
we observed differential mucosal gene expression when comparing healthy controls with IBS-D by microarray 
technology6. In the present study, there was a discrete overlap between differentially expressed genes and proteins 
in IBS-D patients; however, using an integrated analysis of both expression profiles, we identified common signa-
ture pathways, biological functions and disease mechanisms associated with IBS-D (Fig. 3). In particular, cellular 
assembly and cell-to-cell signaling were the most significant biological functions associated with IBS-D (Fig. 3B). 
Moreover, immunological, gastrointestinal and inflammatory diseases were the most relevant disease mechanism 
associated with both IBS-D transcriptional profiles (Fig. 3C).
HC (n = 16) IBS-D (n = 15) P-value
Gender (F:M) 8:8 9:6 —
Age (years; range) 26.1; (22–29) 39.3; (31–47) 0.002
Frequency of abdominal pain (mean; SD) NA 5.7 ± 3.4 —
Severity of abdominal pain (median; CI) NA 47.9; 95% CI [31.8–57.9] —
Stool frequency (median; CI) 1.5; 95% CI [0.8–1.7] 3.0; 95% CI [2.5–4.9] 0.001
Bristol scale(mean; SD) 3.6 ± 0.7 5.1 ± 1.3 0.003
Table 1. Clinical and demographic characteristics of participants. Note: IBS-D, diarrhea-predominant irritable 
bowel syndrome; HC, healthy controls; F, female; M, male; NA, non-applicable. SD: Standard deviation. CI: 
Confidence interval.
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Decreased TESK-1 mediated CFL1-phosphorylation in IBS-D patients. Regulation of actin-based 
motility by Rho is significantly altered at both transcriptomic and proteomic levels in IBS-D (Fig. 3A) which is 
consistent with our previous findings showing cytoskeleton alterations in IBS-D patients7. In addition, 28% of the 
identified altered proteins in IBS-D patients are involved in the dynamic regulation of actin depolymerization 
events (Fig. 1, Fig. 2A and Supplementary Table 2) where CFL1 plays a major role (Fig. 2). In order to validate our 
findings, we have further explored the molecular mechanisms by which actin rearrangement and cytoskeleton 
disruption are linked to the loss of intestinal barrier integrity observed in IBS-D patients7 by analyzing expression 
of actin-binding proteins in a larger cohort of patients and controls. CFL1-mediated actin polymerization regula-
tion is tightly modulated by phosphorylation events driven by specific kinases and phosphatases, (summarized in 
Fig. 2B). No differences in protein expression of total CFL1 were observed (Supplementary Figure 2, Fig. 4A,B); 
however, phosphorylated CFL1 (pCFL1) was reduced in IBS-D patients (Supplementary Figure 2, Fig. 4A,B). In 
concordance, the CFL1 specific kinase TESK1 was down-regulated in IBS-D patients (Supplementary Figure 2, 
Fig. 4A,B) and this down-regulation positively correlated with pCFL1 expression level (Fig. 4C). No significant 
differences in other CFL1 regulatory proteins were found (Supplementary Figure 3). In addition, TESK1 can 
regulate the localization and expression of VCL, which is the protein connecting actin filaments with integrins18. 
Figure 1. Proteomic signature of IBS-D patients. (A) DIGE analysis of protein extracts from jejunal mucosal 
biopsies. Heatmap for the 95 identified spots differentially expressed in IBS-D samples (n = 4) compared to 
healthy control samples (n = 4). Colors represent relative expression levels on a color scale (green: low/red: 
high). A total of 1200 spots were analyzed. 139 showed a >1.3-fold change and, from those, 95 spots were 
identified. Thirty-seven spots showed increased intensity (red-encircled spots), whereas 58 spots showed 
decreased intensity (green-encircled spots). (B) Annotations for the top ten up- and down-regulated spots 
identified in IBS-D vs. healthy control samples. Uniprot accession number, protein symbols and name, and their 




LPS/IL1 mediated Inhibition of RXR funtion 0.0003 2.94E-02 ALDH1B1, SULT1A3/SULT1A4, GSTT1, ALDH1A1, FABP1, SULT2A1
Mitochondrial Dysfunction 0.0003 3.94E-02 SDHA, PRDX3, SOD2, NDUFV2, PARK7
Regulation of Actin-based Motility by Rho 0.0007 4.55E-02 ACTR3, CFL1, ACTA2, ACTA1
VEGF Signaling 0.0008 4.26E-02 YWHAE, GRB2, ACTA2, ACTA1
Clathrin-mediated Endocytosis Signaling 0.0009 3.01E-02 ACTR3, TF, GRB2, ACTA2, ACTA1
RhoA Signaling 0.002 3.81E-02 ACTR3, CFL1, ACTA2, ACTA1
Bile acid biosynthesis 0.002 6.12E-02 ALDH1B1, AKR1A1, ALDH1A1
PI3K/AKT Signaling 0.002 3.03E-02 YWHAE, GRB2, YWHAB, YWHAZ
Actin Cytoskeleton Signaling 0.003 2.21E-02 ACTR3, CFL1, ACTA2, ACTA1
Caveolar-mediated Endocytosis Signaling 0.005 3.70E-02 ALB, ACTA2, ACTA1
Protein Ubiquitination Pathway 0.008 1.85E-02 PSMB3, PSME1, HSPA1A/HSPA1B, PSMB2, HSPA9
Fcγ Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 0.01 3.19E-02 ACTR3, ACTA2, ACTA1
Integrin Signaling 0.01 1.99E-02 ACTR3, GRB2, ACTA2, ACTA1
Glucocorticoid Receptor Signaling 0.03 1.48E-02 HSPA1A/HSPA1B, GRB2, ANXA1, HSPA9
Ephrin Receptor Signaling 0.05 1.55E-02 ACTR3, CFL1, GRB2
Table 2. Canonical signaling pathways most significantly associated with IBS-D protein expression profile. 
*Ratio: number of molecules in the analysis that are associated with the canonical pathway divided by the total 
number of genes that map to the canonical pathway.
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Expression levels of TESK1 correlate with VCL, however, we did not observe significant differences in VCL com-
paring healthy controls with IBS-D (Fig. 4C).
Differential regulation of CFL1-actin activation by sex and disease. To understand the clinical rel-
evance of the molecular changes observed in the CFL1 pathway, we first analyzed the global association between 
pCFL1 and TESK1 expression with IBS-D major symptoms; however, no significant correlations were found 
(Supplementary Table 3). Interestingly, when stratifying groups by sex, we observed that female patients showed 
lower expression levels of pCFL1 and TESK1 compared to male IBS-D patients and healthy controls (Fig. 5A). 
Furthermore, the expression of these proteins negatively correlated with bowel movements in female subjects 
(Supplementary Table 3 and Fig. 5B).
Figure 2. Relationships between differentially expressed proteins in the highest scored network generated by 
IPA where CFL1 has a central role. (A) Protein-protein interaction network showing the differentially expressed 
proteins in IBS-D compared to healthy controls and Canonical Pathways (CP) and Biological Functions 
(Fx) associated to the proteins belonging to this particular network. The intensity of the node color indicates 
the degree of upregulation (red) or down regulation (green). Genes in uncolored nodes were not identified 
as differentially expressed in our proteomic study and were integrated into the computationally generated 
networks on the basis of the evidence stored in the IPA knowledge data base indicating relevance for this 
network. (B) Summary of the actin depolymerization pathway regulated by CFL1.
www.nature.com/scientificreports/
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Discussion
In the present study, we demonstrate that the jejunum of IBS-D patients has a distinctive proteomic profile com-
pared to healthy controls. As an extension of our previous research, the integrative analysis of gene and protein 
expression profiles performed here further supports prior studies describing the loss of intestinal epithelial bar-
rier function as a central molecular mechanism in the disease6,7,10,21,23,27. In addition, we reveal for the first time 
the involvement of TESK1 in human disease, making this protein a potential novel candidate for diagnosis and 
treatment strategies in IBS.
Proteomic approaches have been previously applied to study the colonic mucosa of experimental models 
mimicking IBS  clinical manifestations25,26 and, more recently, Goo et al. reported a distinctive proteomic profile 
in urine samples from IBS patients24. Having studied biological samples from such a different origin (urine vs. 
tissue, rodent vs. human) it is reasonable to expect no common individual proteins across studies. However, 
common pathways and functions (regulation of actin-based motility and actin cytoskeleton signaling) are iden-
tified in both, urine and jejunal tissue, proving the consistency of our data and suggesting that these pathways 
may represent novel candidates for biomarker discovery in IBS. However, further studies comparing tissue and 
urine samples from the same subject will be needed in order to validate proteins from these pathways as potential 
biomarkers.
The actin cytoskeleton is a highly dynamic structure that undergoes rearrangement (polymerization and 
depolymerization) under the control of various actin-binding proteins28,29, including members of the CFL1 fam-
ily and other actin-depolymerizing proteins30,31. Although a decreased expression of total CFL1 in IBS-D could 
not be validated in our study, we observed lower levels of the inactive form of CFL1 (the phosphorylated protein, 
pCFL1)32,33. Reduced pCFL1 would result in increased actin depolymerization events compromising, therefore, 
intestinal epithelial integrity through tight junctions dissassembly and internalization of occludin34,35, altera-
tions previously described in the jejunum of IBS-D patients7. CFL1 phosphorylation is driven by four specific 
kinases LIMK 1 and 2, and TESK1 and 216,17, and counter-regulated by phosphatases, as slingshot and chrono-
phin/PDXP36,37. Although LIMKs are the most studied kinases in CFL1 inactivation, these proteins were not 
altered in IBS-D samples. On the contrary, TESK1 was down-regulated in patient samples and correlated with 
reduced pCFL1, suggesting that TESK1 is a major kinase driving CFL1 inactivation in the small bowel mucosa. 
Another important pathway regulating CFL1 phosphorylation is ROCK-dependent LIMK activation38. Although 
we did not observe differences in total expression of ROCK and LIMK, the activity of this pathway could still be 
depressed due to inactivation of Rho by upstream mechanisms that have not been investigated in the present 
study. In addition, a crucial binding partner of CFL1, WDR1 (also known as actin-interacting protein-1), was also 
identified by our proteomic approach. WDR1 is essential for actin depolymerization kinetics through interaction 
with CFL139. Indeed, a recent study directly implicated WDR1 in the regulation of intercellular junctions and 
Figure 3. IPA comparative analysis of microarray and proteomic expression profiles in IBS-D. (A) Canonical 
signaling pathways; (B) Biological functions; and (C) Diseases and disease mechanisms most significantly 
associated with IBS-D transcriptomic (dark blue) and proteomic (light blue) profiles. The significance value 
associated with each category is a measure of the likelihood that the association between dysregulated 
transcripts and a given category is due to random chance. The x-axis of each graph shows the significance, 
expressed as the negative exponent of the P-value calculation for each category, increasing with bar height. The 
orange line shows a threshold P-value of 0.05.
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barrier properties of intestinal epithelial cell monolayers40. Hence, upregulation of WDR1 could interact with 
CFL1 dephosphorylation to stimulate F-actin turnover and destabilize junction-associated actin cytoskeleton 
in the intestinal mucosa in IBS-D. Alterations in CFL1 pathway may, therefore, be involved in the complex reg-
ulatory network of molecular mechanisms underlying increased intestinal epithelial permeability described in 
IBS-D. Remarkably, although TESK1 has been described to play a key role in integrin-mediated actin reorganiza-
tion through phosphorylating and inactivating CFL1 and it has been found expressed in epithelial colon cancer 
cells41, no studies so far have provided evidence of a major role of this protein in any human disease mechanism. 
Our study represents the first report showing the association of TESK1 expression in human disease, in particular 
in female subjects. Indeed, a remarkable finding in this work is the identification of sex-dependent differences in 
CFL1 regulation. In particular, phosphorylation of CFL1 and expression levels of TESK1 are lower and correlated 
Figure 4. Expression analysis CFL1 signaling pathway in IBS-D. (A) Representative Western blot image 
showing expression of pCFL1, CFL1, TESK1 in the jejunal mucosa of four controls and four patients with 
IBS-D. (B) Normalization was performed using actin as loading control. Bands were quantified and results 
are expressed as fold-change respect to the average of the control group. Comparisons were performed by 
the Mann-Whitney U test (P-values shown). (C) Correlation between the CLF1 phosphorylation levels and 
VCL expression with TESK1 expression performed by Spearman correlation (rs and P-values shown). HC are 
represented with circles and IBS-D patients with squares. AU: arbitrary units.
www.nature.com/scientificreports/
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with bowel habits in female IBS-D patients. However, these results should be taken with caution, since the num-
ber of subjects is relatively low in each group. Although the relation between sex and cytoskeleton alterations 
is not clear, a possible explanation could be found in the role of female sexual hormones in the modulation of 
actin dynamics42. Indeed, estradiol regulates actin cytoskeletal dynamics in the hippocampus and endothelium 
through ROCK and Rac/p21-activated kinase signaling pathways43,44. In addition, estrogen treatment increases 
pCFL1 and, in consequence, actin polymerization events45. The connection between actin cytoskeleton rearrange-
ments and sex could, therefore, help to shed some light on the mechanisms associated to the female bias that exist 
in IBS and, indeed, merit further investigation.
In addition to the actin cytoskeleton-related pathways, LPS/IL1 mediated alterations of nuclear RXR receptors 
and mitochondrial dysfunctions were identified by IPA analysis with higher significance. Higher concentration 
of both LPS and IL1 have been previously reported in IBS46–49 and related to alterations in permeability in cell 
culture models46. IBS patients have also showed higher expression of IL1 alpha and beta in the duodenum, which 
correlate with small intestinal bacterial overgrowth, bloating, and diarrhea. Furthermore, IL1beta concentration 
was higher in peripheral blood mononuclear cells supernatants from IBS-D, compared to healthy controls and 
IBS with constipation, and related with direct stimulation of colonic afferents via TTX-sensitive ion channels and 
mechanical hypersensitivity. On the other hand, mitochondrial dysfunction is an interesting finding in the jeju-
nal mucosa of IBS-D patients. In this line, we have described significant alterations in mitochondrial enzymatic 
expression, activity, and morphology in the IBS-like model of crowding stress50,51. These findings may be linked 
to the cytoskeleton alterations we have previously described in IBS-D7 due to the ATP dependence of the actin 
polymerization homeostasis which make this process vulnerable to alterations in mitochondrial function30. In 
fact, estrogen stimulation of epithelial breast cancer cells lead to mitochondrial reactive oxygen species produc-
tion, which can be increased with the actin disruption and integrin activation52. These effects link our observa-
tions, but more studies will be necessary to connect all these pieces together.
Finally, we would like to acknowledge the limitations associated with the approach taken in this study. First, 
the correlation between transcriptome and proteome data is low. Indeed, the transcriptomic and proteomic inde-
pendent analysis do not match in the same genes/proteins, however, by integrating data, we identify the same 
biological pathways and functions. In fact, this multi-omic strategy points to a robust effect of the CFL1 pathway 
regulating cytoskeleton dynamics and epithelial permeability in IBS-D14,53,54. In addition, it should be taken into 
account that none of the high-throughput techniques applied here is able to reflect the post-translational events 
like protein degradation rates and phosphorylation and cellular localization which are known to alter protein 
half-lives and their detection. Indeed, all three post-translational mechanisms (proteasome degradation, phos-
phorylation and protein delocalization) have been identified to affect proteins involved in intestinal epithelial 
integrity in IBS, nor in this study neither in previous reports6,7,23,55. In addition, and related to the former point, 
several critical proteins involved in intestinal epithelial integrity are absent from our proteomic data. In particular, 
proteins within the major networks responsible for apical junction stabilization and actin dynamics. This may 
reflect technical issues with the sensitivity of the proteomics methods available and parameters (for example, 
false negative and low maximum mass range for peptides with post-translational modifications). Indeed, we took 
Figure 5. Expression analysis CFL1 signaling pathway in IBS-D samples divided by sex. (A) Normalization 
was performed using actin as loading control. Bands were quantified and results are expressed as fold-
change respect to the average of the control group. Comparisons were performed by the Mann-Whitney U 
test (P-values shown). (B) Correlation between pCFL1 and TESK1 levels and number of bowel movements 
performed by a Spearman correlation (rs and P-values shown). HC females are represented with circles and 
IBS-D female patients with squares. AU: arbitrary units.
www.nature.com/scientificreports/
8SCIENTIFIC RepoRts |  (2018) 8:2255  | DOI:10.1038/s41598-018-20540-9
a non-targeted proteomics approach which has certain technical limitations. However, using a more targeted 
approach, as we did previously for the apical junctional proteins core proteins7 and for TESK1 and other proteins 
belonging to the CFL1 pathway here, we could identify alterations in these specific proteins in the jejunal mucosa.
In conclusion, our findings support an altered regulation of cytoskeleton dynamics in the small bowel mucosa 
of IBS-D, particularly in female patients. We show evidence of the involvement of a novel mechanism in bowel 
dysfunction by TESK1-mediated regulation of CFL1 pathway which may contribute to the female predisposition 
to suffer IBS. Further understanding of the mechanisms involving sex-mediated regulation of mucosal epithelial 
integrity may have significant preventive, diagnostic, and therapeutic implications for IBS.
Material and Methods
Participants. Recently diagnosed, naïve IBS-D patients meeting the Rome III criteria56 were prospectively 
recruited from the outpatient gastroenterology clinic. Healthy control subjects were recruited by public adver-
tising, as a control group. Prior to inclusion, a complete medical history and physical examination was carried 
out in all participants. Food allergy was ruled out using a battery of skin prick tests (Leti, Madrid, Spain) for 32 
common food allergens with histamine and saline as positive and negative controls, respectively. Candidates 
with either positive reaction by skin prick tests or clinical history consistent with food allergy (digestive and/or 
extra-digestive symptoms associated with exposure to certain food components) were excluded. Other exclu-
sion criteria included age <18 or >70 years, major psychiatric and organic diseases, past episodes of infectious 
gastroenteritis and gastrointestinal comorbidities, drug or pharmaceutical compound intake in the last 2 weeks, 
steroids, anti-allergic or immunosuppressive and related drugs in the last 3 months and radiotherapy or chemo-
therapy in the last 6 months. Written informed consent was obtained from each participant and data was stored 
in an anonymous fashion according to the approval from the ethics committee of the Institut de Recerca Hospital 
Universitari Vall d´Hebron (PR(AG)221/2015). All methods were performed in accordance with our institution 
guidelines and regulations.
Clinical assessment. The following parameters were recorded in all participants using daily questionnaires 
over a 10-day period before the biopsy: a) the severity of abdominal pain by a 100-point visual analogue scale; 
b) the frequency of abdominal pain (number of days with pain); c) the stool frequency (number of bowel move-
ments/day); d) the stool consistency by the Bristol stool form score57.
Experimental design and procedures. In order to narrow down the molecular pathways involved in the 
origin of IBS-D patients we have combined part of our previously published transcriptomic data7 (data set avail-
able at the NCBI Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/geo; accession number GSE14841) 
with the proteomic profile we have generated in this study. Common pathways and biological functions were 
subsequently identified using IPA and the most relevant candidates were then further followed-up using comple-
mentary and more sensitive approaches in a higher number of patients and controls. Ultimately, obtained data 
was correlated with clinical data from patients and controls in order to understand the significance of our results.
Tissue samples were obtained as follows. A single mucosal biopsy per participant was obtained from the prox-
imal jejunum, 5–10 cm distal to the Treitz’s angle, using a modified Watson’s capsule as described previously58. 
Tissue samples were immediately snap frozen in liquid nitrogen for protein analysis as described below.
The following analyses were subsequently performed (Supplementary Figure 1). Detailed description of pro-
cedures is given in the supplementary material and methods section.
 (a) Proteomic profiling by two-dimension difference in-gel electrophoresis (2D-DIGE) analysis: total protein 
was isolated from jejunal biopsies of a discovery cohort comprising four healthy controls and four IBS-D. 
Protein lysates were labeled with either Cy3 or Cy5 cyanine dye to distinguish proteins from healthy 
controls or IBS-D and 2D-DIGE was performed with pooled samples. Cy3 and Cy5 images were scanned 
and analyzed for determination of significant alterations in protein abundances using the DeCyder V. 5.0 
software59.
 (b) Protein identification and data analysis: protein spots with higher differences in expression were picked 
from the gel and digested with trypsin60. Peptide mass fingerprint of proteins was obtained by MALDI-
TOF-TOF mass spectrometry and identification through database searches were performed using by 
Mascot algorithm61. Identified proteins were submitted to the IPA software for the pathway analysis6.
 (c) Validation of profiling results by western blot: for validation, we included 12 additional controls and 11 
additional IBS-D patients. Protein homogenates were separated by electrophoresis and blotted to a polyvi-
nylidene fluoride (PVDF) membrane. Detection of proteins belonging to specific pathways was performed 
with primary antibodies listed in Supplementary Table 1. All blots were probed with anti-β-actin anti-
body as a protein loading control. The bands were scanned and quantitated by densitometry (ImageJ 1.50 
software) on the same immunoblot. Values were normalized to β-actin expression and fold-change was 
calculated for each sample respect to the average of the control group.
Pathway and network analysis. To identify relevant biological pathways implicating those genes and 
proteins differentially expressed, we applied the IPA methodology (IPA Software, Ingenuity® Systems, www.inge-
nuity.com). IPA integrates selected omics data sets (genomics, transcriptomics, proteomics) with mining tech-
niques to predict functional connections and their interpretation in the context of protein networks that comprise 
protein-protein interactions and related biological functions and canonical signaling pathways. Two types of 
analysis were performed in our omics data. Further details are given in the supplementary material and methods.
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 (1) Proteomic core analysis to identify the most relevant biological functions and pathways associated to the 
differentially expressed proteins followed by protein network analysis. For network analysis, IPA computed 
a score (P-score = −log10(P-value)) according to the fit of the set of supplied genes and a list of biological 
functions stored in the IPKB. The score takes into account the number of proteins in the network and the 
size of the network to approximate how relevant this network is to the original list of genes and allows the 
networks to be prioritized for further studies. In addition, the functions and pathways associated with the 
proteins in the networks are also identified.
 (2) Transcriptomic (from reference6) and proteomic integrative analysis to identify common biological func-
tions and pathways.
Statistical analysis. Statistical analysis of proteomic data: image analysis and statistical quantification 
of relative protein abundances were performed using DeCyder V. 6.0 software (GE Healthcare). Differentially 
expressed proteins were selected applying a 1.3 fold threshold and P < 0.05.
Statistical analysis for western blot: two-tailed parametric or non-parametric tests were used as appropriate 
(unpaired Student’s t-test, Mann-Whitney U test, respectively) using GraphPad Prism 5.0 software. Relationship 
between clinical variables and gene expression were assessed by Spearman’s correlation rho. Data are expressed as 
mean ± standard deviation (SD), unless otherwise stated.
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